SynCore Biotechnology (Taiwan) Insiders
| 4192 Stock | TWD 34.85 0.05 0.14% |
SynCore Biotechnology employs about 65 people. The company is managed by 8 executives with a total tenure of roughly 47 years, averaging almost 5.0 years of service per executive, having 8.13 employees per reported executive. Recap of SynCore Biotechnology's management performance can provide insight into the venture performance.
| ChihWen Lee Chairman Chairman of the Board |
SynCore |
SynCore Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4348) %, meaning that it generated substantial loss on money invested by shareholders. SynCore Biotechnology's management efficiency ratios could be used to measure how well SynCore Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.SynCore Biotechnology Workforce Comparison
SynCore Biotechnology Co is rated third in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 357. SynCore Biotechnology retains roughly 65.0 in number of employees claiming about 18% of stocks in Biotechnology industry.
SynCore Biotechnology Notable Stakeholders
A SynCore Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SynCore Biotechnology often face trade-offs trying to please all of them. SynCore Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SynCore Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| ChihWen Lee | Chairman of the Board | Profile | |
| ChiaHao Liang | Senior Manager of Finance & Accounting | Profile | |
| MuhHwan Su | General Manager | Profile | |
| WenHsin Huang | VP Department | Profile | |
| FernFang Lin | VP Devel | Profile | |
| CharnJung Chang | General Manager-Ophthalmology Project | Profile | |
| HuiHung MBA | VP Drugs | Profile | |
| RueyWen Lin | Head Department | Profile |
About SynCore Biotechnology Management Performance
The success or failure of an entity such as SynCore Biotechnology often depends on how effective the management is. SynCore Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SynCore management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SynCore management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people.
Please note, the imprecision that can be found in SynCore Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SynCore Biotechnology Co. Check SynCore Biotechnology's Beneish M Score to see the likelihood of SynCore Biotechnology's management manipulating its earnings.
SynCore Biotechnology Workforce Analysis
Traditionally, organizations such as SynCore Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SynCore Biotechnology within its industry.SynCore Biotechnology Manpower Efficiency
Return on SynCore Biotechnology Manpower
| Revenue Per Employee | 106.8K | |
| Revenue Per Executive | 867.4K | |
| Net Loss Per Employee | 7.1M | |
| Net Loss Per Executive | 57.3M |
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.